```html

Jesper’s Disease (Hepatic Lipidosis)

Overview

Jesper’s disease, more formally known as hepatic lipidosis or fatty liver disease, is a condition in which excess fat accumulates within liver cells, impairing normal liver function. Although the term is used most often in veterinary medicine (especially in cats), a comparable metabolic disorder exists in humans and is typically referred to as non‑alcoholic fatty liver disease (NAFLD). The guide below focuses on the human form of the disease.

• Who it affects: Adults of any age, but prevalence rises sharply after age 40. Women are slightly more likely than men to develop NAFLD.
• Prevalence: Global estimates suggest that 25‑30 % of the adult population has NAFLD, making it the most common chronic liver disease worldwide (WHO, 2022). In the United States, > 84 million adults are affected (CDC, 2023).

Symptoms

Many people with early hepatic lipidosis have no symptoms, which is why routine screening is essential for at‑risk individuals. When symptoms do appear, they often develop gradually.

Common clinical features

• Fatigue & weakness: Persistent tiredness not explained by other causes.
• Right‑upper‑quadrant (RUQ) discomfort: Dull ache or pressure under the rib cage.
• Abdominal fullness or bloating: A sensation of “pressure” after meals.
• Unexplained weight loss: Even though the liver stores excess fat, metabolic dysregulation can cause loss of lean body mass.
• Loss of appetite (anorexia): May precede weight loss.
• Jaundice (yellowing of skin & eyes): Typically appears later, indicating more advanced disease.
• Pruritus (itching): Due to bile salt accumulation.
• Dark urine & pale stools: Sign of impaired bilirubin excretion.
• Elevated blood sugar or new‑onset type 2 diabetes: Hepatic insulin resistance is a key driver.

Causes and Risk Factors

Hepatic lipidosis results from an imbalance between the import, synthesis, oxidation, and export of fatty acids in the liver.

Primary causes

• Obesity: Excess caloric intake leads to increased free fatty acids delivered to the liver.
• Insulin resistance: Common in metabolic syndrome; impairs the liver’s ability to oxidize fat.
• Excessive fructose or sugary beverage consumption: Promotes de novo lipogenesis.
• Medications: Corticosteroids, amiodarone, tamoxifen, and certain antiretrovirals can precipitate fatty infiltration.
• Genetic predisposition: Variants in PNPLA3, TM6SF2, and MBOAT7 genes increase susceptibility (NIH, 2021).

Risk factors

• Body mass index (BMI) ≥ 30 kg/m²
• Type 2 diabetes mellitus or pre‑diabetes
• Hyperlipidemia (high triglycerides, low HDL)
• Hypertension
• Polycystic ovary syndrome (PCOS)
• Sedentary lifestyle
• Older age (≥ 40 years)
• Family history of NAFLD or liver disease

Diagnosis

Because early disease is often silent, diagnosis typically involves a combination of clinical assessment, laboratory testing, and imaging.

Step‑by‑step diagnostic pathway

1. Medical history & physical exam – Focus on metabolic risk factors, alcohol intake, medication list, and RUQ tenderness.
2. Blood tests
   • Serum aminotransferases (ALT, AST): usually mildly‑elevated; ALT > AST is typical.
   • Alkaline phosphatase & gamma‑glutamyltransferase (GGT): may be modestly raised.
   • Lipid panel, fasting glucose, HbA1c: assess metabolic syndrome.
   • Serum albumin, bilirubin, coagulation profile: gauge liver synthetic function.
3. Imaging
   • Ultrasound: First‑line; detects increased echogenicity consistent with steatosis.
   • Transient elastography (FibroScan®): Measures liver stiffness; helps differentiate simple steatosis from fibrosis.
   • CT or MRI: More precise quantification of fat; MRI‑PDFF is the reference standard.
4. Liver biopsy (optional) – Reserved for uncertain cases or when there is suspicion of non‑alcoholic steato‑hepatitis (NASH) with fibrosis. Histology remains the gold standard.

Treatment Options

There is no single “pill” that cures hepatic lipidosis. Management centers on reversing the underlying metabolic drivers and preventing progression to fibrosis or cirrhosis.

Lifestyle modifications (first‑line)

• Weight loss: 7‑10 % reduction in body weight improves steatosis in > 80 % of patients (Mayo Clinic, 2022).
• Dietary changes:
  • Adopt a Mediterranean‑style diet – emphasis on whole grains, legumes, nuts, fish, olive oil, and plenty of vegetables.
  • Limit added sugars, refined carbs, and saturated fats.
  • Consider a modest caloric deficit of 500‑750 kcal/day.
• Physical activity: ≥ 150 minutes/week of moderate‑intensity aerobic exercise plus resistance training twice weekly.

Medications

• Vitamin E (800 IU/day): Shown to improve histology in non‑diabetic NASH patients (Cleveland Clinic, 2021). Use with caution in diabetics or those at risk for bleeding.
• Pioglitazone: A thiazolidinedione that improves insulin sensitivity; beneficial in biopsy‑proven NASH, especially with diabetes.
• GLP‑1 receptor agonists (e.g., liraglutide, semaglutide): Recent trials demonstrate reduction in liver fat and inflammation.
• Statins: Safe for most patients with NAFLD and recommended for dyslipidemia; they do not worsen liver disease.

Procedural & advanced therapies

• Bariatric surgery: Gastric bypass or sleeve gastrectomy yields > 70 % resolution of steatosis and reduces fibrosis risk in severely obese patients.
• Clinical trials: Agents targeting fibrosis pathways (e.g., obeticholic acid, selonsertib) are under investigation.

Living with Jesper’s Disease (Hepatic Lipidosis)

Effective long‑term management hinges on daily habits that support liver health.

Practical daily‑life tips

• Meal planning: Keep a food diary, aim for balanced plates (½ veg, ¼ lean protein, ¼ whole grains).
• Hydration: 8‑10 glasses of water daily help maintain bile flow.
• Limit alcohol: Even modest intake can worsen fatty liver; most guidelines recommend < 14 g per week for men and < 7 g for women, or complete abstinence if liver enzymes are markedly elevated.
• Regular monitoring: Annual labs (ALT/AST, fasting glucose, lipids) and imaging (ultrasound or FibroScan) as advised by your clinician.
• Weight‑maintenance strategies: Use wearable activity trackers, set realistic goals (0.5‑1 kg/month loss initially).
• Stress management: Chronic stress can exacerbate insulin resistance; incorporate mindfulness, yoga, or counseling.
• Medication adherence: Take prescribed agents with food as directed; inform your doctor of any side‑effects.

Prevention

Because hepatic lipidosis is fundamentally a metabolic disease, primary prevention mirrors heart‑disease prevention.

• Maintain a healthy BMI (18.5‑24.9 kg/m²).
• Follow a plant‑rich, low‑sugar diet.
• Engage in regular physical activity.
• Control blood pressure, glucose, and lipids.
• Avoid excessive alcohol and hepatotoxic medications when possible.
• Screen high‑risk individuals (obesity, type 2 diabetes, metabolic syndrome) with yearly liver enzyme tests.

Complications

If left unchecked, hepatic lipidosis can advance through a spectrum of liver injury:

• Non‑alcoholic steato‑hepatitis (NASH): Inflammation and ballooning of hepatocytes.
• Fibrosis: Scarring that may progress to cirrhosis; estimated to affect 15‑20 % of NAFLD patients over 10 years.
• Cirrhosis: End‑stage liver disease with portal hypertension, varices, and risk of hepatic encephalopathy.
• Hepatocellular carcinoma (HCC): Risk is 2‑3 times higher in patients with NASH‑related cirrhosis.
• Cardiovascular disease: The leading cause of death in NAFLD patients, due to shared metabolic risk factors.

When to Seek Emergency Care

---

**Sources:** Mayo Clinic, 2022; CDC, National Center for Health Statistics, 2023; WHO Global Health Estimates, 2022; NIH, National Institute of Diabetes and Digestive and Kidney Diseases, 2021; Cleveland Clinic, 2021; peer‑reviewed journals Hepatology, Journal of Hepatology, and Lancet Gastroenterology. Consult your healthcare provider for personalized advice.

```